Aurinia Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Aurinia Pharmaceuticals Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Aurinia Pharmaceuticals Inc Competitors
Aurinia Pharmaceuticals Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans